



IDT Australia Ltd - Appointment of Director

***Global pharmaceutical operations expertise
Successful track record growing and integrating complex businesses
Marks a continuation of IDT's commitment to growing a successful international
pharmaceutical business***

1 March 2017, Melbourne: IDT Australia Limited (IDT) announces that **Ms. Mary Sontrop** has been appointed as a Director of the IDT Board, effective today.

Ms. Sontrop is a seasoned pharmaceutical executive with extensive international experience in the life sciences industry. She has held a number of executive roles within CSL Limited, including most recently Executive Vice President of Global Operations, CSL Behring and Managing Director, ZLB Behring GmbH. In these roles and others she was responsible for integrating and building global manufacturing networks servicing Europe, the USA and elsewhere. Prior to this she held other senior international roles within CSL across multiple areas, including commercial, quality and operations.

“We welcome Mary to the IDT board as part of our ongoing restructure to meet the growth opportunities in our generics business model” said IDT’s Chairman, Mr. Graeme Kaufman “Mary brings broad global pharma experience, with demonstrated success in growing and integrating international businesses. Her operations expertise will complement the experience of the current board.”

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT Australia Ltd is developing a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.